论文部分内容阅读
目的:探讨乳腺浸润性导管癌(invasive ductal carcinoma,IDC)中成纤维细胞生长因子受体1(fibroblast growth factor receptor 1,FGFR1)和乳腺癌扩增性抗原1(amplified in breast cancer 1,AIB1)的表达,分析两者与乳腺IDC临床特征的关系以及两者的相关性。方法:采用免疫组织化学SP法检测2006-01-01-2011-06-30河北省人民医院100例经病理科医师确诊、临床病例资料完整的乳腺IDC组织石蜡标本中FGFR1及AIB1的表达情况,分析两者与临床病理特征的关系及两者的相关性。统计所有数据均采用SPSS 17.0统计软件进行分析,采用χ2检验或Fisher确切概率法对同一指标的不同临床病理特征进行比较,应用多因素Logistic回归分析FGFR1及AIB1阳性表达有关的因素,采用Spearman等级相关分析乳腺IDC中FGFR1和AIB1表达的相互关系。结果:FGFR1在乳腺IDC中的阳性表达率为31.00%,其表达与腋窝淋巴结转移(42.86%vs 22.41%)、病理组织学分级(Ⅰ级0,Ⅱ级26.80%,Ⅲ级51.60%)和临床分期(Ⅰ期11.10%,Ⅱ期29.40%,Ⅲ期65.00%)有关,差异均有统计学意义,χ2值分别为4.760、12.463和15.671,P值分别为0.029、0.002和<0.001;AIB1在乳腺IDC中的阳性表达率为75.00%,与腋窝淋巴结转移与否(83.33%vs68.97%)有关,差异有统计学意义(χ2=4.433,P=0.035),其表达随着病理组织学分级(Ⅰ级38.46%,Ⅱ级75.00%,Ⅲ级90.32%)和临床分期(Ⅰ期44.44%,Ⅱ期84.31%,Ⅲ~Ⅳ期95.00%)的增高而逐渐增高,差异均有统计学意义(χ2=13.138,P=0.001;χ2=20.336,P<0.001);多因素Logistic回归分析显示,组织学分级是影响FGFR1及AIB1阳性表达的最主要因素(waldχ2=13.448,P=0.003;waldχ2=7.958,P=0.001)。FGFR1与AIB1表达在乳腺IDC中呈正相关,r=0.237,P=0.017。结论:FGFR1及AIB1与乳腺IDC的淋巴结转移、病理组织学分级及临床分期有关,提示两者与乳腺IDC的发生和发展密切相关,且两者表达呈正相关,联合检测两者可能对乳腺IDC的预后判断更有价值。
Objective: To investigate the expression of fibroblast growth factor receptor 1 (FGFR1) and amplified in breast cancer 1 (AIB1) in invasive ductal carcinoma (IDC) The relationship between the two and the clinical features of breast IDC and their correlation were analyzed. Methods: Immunohistochemical SP method was used to detect the expression of FGFR1 and AIB1 in 100 cases of idiopathic breast cancer IDC tissues confirmed by pathologists from January 2006 to January 2011 in People's Hospital of Hebei Province. To analyze the relationship between the two and clinicopathological features and their correlation. Statistical analysis All data were analyzed by SPSS 17.0 statistical software. Chi-square test or Fisher exact test were used to compare the different clinicopathological features of the same index. Multivariate logistic regression analysis was used to analyze the factors related to the positive expression of FGFR1 and AIB1. Spearman rank correlation The correlation between FGFR1 and AIB1 expression in mammary IDCs was analyzed. Results: The positive expression rate of FGFR1 in breast IDC was 31.00%. The positive expression rate of FGFR1 in breast IDC was 42.86% (22.41%) with axillary lymph node metastasis (11.10% in stage Ⅰ, 29.40% in stage Ⅱ and 65.00% in stage Ⅲ), the differences were statistically significant (χ2 = 4.760,12.463 and 15.671, P = 0.029,0.002 and <0.001, respectively) The positive expression rate in IDC was 75.00%, which was correlated with axillary lymph node metastasis (83.33% vs68.97%) (χ2 = 4.433, P = 0.035). The positive expression rate of IDC in histological grade Ⅰ grade 38.46%, grade Ⅱ 75.00%, grade Ⅲ 90.32%) and clinical stage (stage Ⅰ 44.44%, stage Ⅱ 84.31%, stage Ⅲ ~ Ⅳ 95.00%) increased and gradually increased, the differences were statistically significant (χ2 = 13.138, P = 0.001; χ2 = 20.336, P <0.001). Multivariate Logistic regression analysis showed that histological grade was the most significant factor affecting the expression of FGFR1 and AIB1 (waldχ2 = 13.448, P = 0.003; P = 0.001). FGFR1 and AIB1 expression in breast IDC was positively correlated, r = 0.237, P = 0.017. Conclusions: FGFR1 and AIB1 are associated with lymph node metastasis, histopathological grade and clinical stage in breast IDC, suggesting that both of them are closely related to the occurrence and development of breast IDC, and their expression is positively correlated with each other. Prognosis is more valuable.